Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected almost every country in the world since De-cember 2019. Despite the efforts of the human race to combat the virus, we are still looking for an evidence-based permanent cure for the disease. Ivermectin has recently emerged as one of the therapies having a beneficial effect on COVID-19. Ivermectin, owing to its properties, continues to be a possible treatment against the COVID-19 disease. Already being a mainstream drug with minimal adverse effects, it garners valid consideration. It's use in hospitalized patients, randomized controlled trials, and observational studies has also supported its implementation. In this article, we have reviewed recent studies and explored the effectiveness of ivermectin in hospitalized COVID-19 patients.
Highlights
SARS-CoV-2 is a single-stranded RNA virus from the Coronaviridae family
The aim of this review is to provide a synopsis of the literature on the interaction between COVID-19 and ivermectin while trying to gauge the potential use of the drug against this devastating disease
We chose randomized controlled trials (RCTs) and observational studies in the English language that evaluated the effectiveness of ivermectin on COVID-19 patients compared against standard treatment protocol, placebo, or other prospective medications in their study
Summary
SARS-CoV-2 is a single-stranded RNA virus from the Coronaviridae family. There are 7 known species of the coronavirus that have the ability to infect humans. Studies have shown non-conclusive or insignificant evidence when it comes to patient mortality and other outcomes like disease progression, time to clinical stability, need of invasive ventilation, and duration of hospital stay [2,3,4,5,6,7]. This leaves the door open for debates on the efficacy of these drugs and whether clinicians should consider using them. Only corticosteroids have shown consistent encouraging signs towards a favorable prognosis of the disease [8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
